AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06706804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wipe Bathing
Description: In groups of 2-3 pregnant women in this group, the researcher will explain the stages of newborn wiping bath application on the newborn model, and then the pregnant women will individually apply the bath on the model. The trainings will be held in the pregnant school at the appropriate times, or in an empty room determined by the hospital administration if there is another planned training in the pregnant school. In the wiping bath training, women will be provided to perform the procedure on the model appropriate to the gender of their babies for genital area cleaning based on the gender of newborns. After the training, pregnant women will be given a home follow-up form to record the first bath time of their babies after birth, the umbilical cord fall time and the body temperature of their babies (before bathing, immediately after bathing and 10 minutes after bathing) and will be told how to fill it out.
Study NCT06709417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg iv Q3W
Study NCT06709417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Liposomal paclitaxel: 150mg/m2, Q3W + cisplatin: 75mg/m2, Q3W (combined with PD-1 therapy) Liposomal paclitaxel: 50mg/m2, Q3W + cisplatin: 20mg/m2, Q3W (combined with radiotherapy )
Study NCT06709417 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: The total dose is 5040cCy in 28 fractions (5 days per week, 1.8 Gy/day).
Study NCT06708000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical Likelihood (CL) Model-Based Diagnostic Strategy
Description: The Clinical Likelihood (CL) model-based diagnostic strategy utilizes two models: the RF-CL model and the CACS-CL model. These models assess the pre-test probability of obstructive coronary artery disease (CAD) based on patient factors such as age, sex, symptoms, and traditional cardiovascular risk factors like smoking, diabetes, and hypertension. The CACS-CL model incorporates coronary artery calcium scoring to further refine the risk assessment. Patients identified with a low likelihood of CAD may avoid unnecessary diagnostic testing, such as cardiac CT, while maintaining diagnostic accuracy and safety. This approach aims to optimize resource use, reduce patient burden, and focus on other potential causes of symptoms when CAD is unlikely.
Study NCT06708000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment
Description: Patients will follow the standard diagnostic pathway, which includes the use of cardiac CT and other advanced diagnostic procedures based on clinical guidelines. This approach is the current standard of care for patients with suspected obstructive coronary artery disease (CAD). The control group allows for comparison of outcomes with those in the intervention arm, particularly in terms of resource utilization, patient safety, and diagnostic accuracy.
Study NCT06708455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-201 Rapamycin Resistant T Cells
Description: Autologous Rapamycin-Resistant Th1/Tc1 Cells
Study NCT06708455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Prior to RAPA-201 Therapy
Description: Carboplatin + Paclitaxel Regimen (CP Regimen)
Study NCT06709027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention Group (Mobile Health Management Intervention)
Description: Participants in this group will receive a mobile health management intervention over a period of 12 weeks. This intervention includes the use of a mobile application designed for health management, psychological support, and monitoring,et al， with the aim of improving the mental health status of elderly patients with depression.
Study NCT06706856 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR exam
Description: Participants will undergo an advanced magnetic resonance (MR) examination of the abdomen and liver.
Study NCT06706856 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: US exam
Description: Participants will undergo an abdominal ultrasound (US) examination using a full-size US system. Some participants may undergo a point-of-care abdominal US exam with a handheld US system, if possible.
Study NCT06706856 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Participants will undergo a blood draw of approximately 25 mL volume.
Study NCT06706856 — intervention group
Intervention type: OTHER
Intervention: Physical measurements
Description: Participants will have their height, weight and waist circumference measured. Vital signs including respiratory frequency, heart rate, temperature, and blood pressure will be measured.
Study NCT06706856 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be asked to fill out questionnaires to collect information about their prescribed medications, demographics, medical and surgical histories, prior laboratory results, physical activity and lifestyle measures, and potential alcohol intake (AUDIT questionnaire).
Study NCT06709703 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinematic aligned total knee replacement
Description: Replacement of worn knee cartilage using a prosthesis. The alignment is determined according to the patient's anatomy and ligament balance.
Study NCT06709703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinematic aligned total knee replacement
Description: Replacement of worn knee cartilage using a prosthesis. The alignment is determined according to the patient's anatomy and ligament balance.
Study NCT06707532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Induction of anaesthesia:~* Fentanyl 1-3ug/kg/m.c i.v.~* Ketamine 50mg i.v.~* Propofol 1.5-2mg/kg/m.c i.v.~* Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.>60kg) i.v. Precurarisation~* Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -> Intubation~Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA:~- In case of ventilatory distress pPeak >30 cm H2O ad hoc Propofol 0.25-0.75mg/kg/m.c i.v.~Elimination of neuromuscular blockade:~- To exclude residual relaxation after pre-curative: 1mg Atropine i.v. + 0.5mg Neostigmine i.v.
Study NCT06707532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Induction of anaesthesia:~* Fentanyl 1-3ug/kg/m.c i.v.~* Ketamine 50mg i.v.~* Propofol 1.5-2mg/kg/m.c i.v.~* Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.>60kg) i.v. Precurarisation~* Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -> Intubation~Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA:~- rocuronium 0.1-0.3mg/kg/m.c i.v. For TOF \<2~Abolition of neuromuscular blockade:~- Atropine 1-1.5mg i.v. + 1-3mg Neostigmine i.v. Or Sugammadex 2-4mg/kg/m.c i.v.
Study NCT06707350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: 8 cycles of 5-minute inflation and 5-minute deflation on 2 upper and lower limbs with a blood pressure cuff
Study NCT06707350 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham condition (control group)
Description: 8 cycles of 5-minute inflation to a pressure of 20 mm Hg followed by 5-minute cuff deflation.
Study NCT06707103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR987 0.1% gel
Description: 6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)
Study NCT06707103 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of Care (wound cleansing/dressings and compression bandaging)
Study NCT06706921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclovine PET/CT Scan
Description: In this prospective study, an 18F-Fluciclovine PET/CT will be additionally obtained at baseline (pre-LuPSMA RLT), and after the 2nd, 4th, 6th LuPSMA RLT cycles.18F-Fluciclovine PET/CT will be acquired within 7 days from the PSMA PET.
Study NCT06709183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention-Control
Description: Nurses in this group will start the first oral care practice by using the oral care retractor on the model. Before starting the procedure, the nurses will fill in the 'Beck Mouth Assessment Guide' and after the procedure, they will fill in the 'Oral Care Practices Evaluation Form'. A rest period of at least 10 minutes will be provided before the second oral care application. Standard oral care will be applied during the second application. Similarly, nurses will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Assessment Form' after the procedure. At the end of both procedures, nurses will complete the 'Quebec Assistive Technology User Satisfaction Assessment Questionnaire (Q-ATUSA)' and the 'Interview Form'. The 'Interview Form' will be used to collect nurses' experiences and opinions about the oral care procedure. During the interview, audio recordings will be made with the knowledge of the nurses.
Study NCT06709183 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control - intervention
Description: In the first oral care procedure, nurses in this group will perform standard oral care on the model without using the oral care retractor. They will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Evaluation Form' after the procedure. There will be a rest period of at least 10 minutes before the second oral care procedure. During this procedure, the second group of nurses who initially perform standard oral care will perform oral care using an oral care retractor. Similarly, they will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Evaluation Form' after the procedure. At the end of both procedures, nurses will complete the 'Quebec Assistive Technology User Satisfaction Assessment Questionnaire (Q-ATUSA)' and the 'Interview Form'. The 'Interview Form' will be used to obtain nurses' experiences and opinions regarding oral care practices..
Study NCT06709144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SMA lymph node dissection
Description: The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA)
Study NCT06709144 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMV lymph node dissection
Description: The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)
Study NCT06482814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (sleep restriction)
Description: During the experimental segment the sleep opportunity will be restricted to 5 hours/night. During the acclimation and recovery phases a 9-hour/night sleep opportunity will be provided.
Study NCT06482814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal sleep
Description: During the normal sleep condition a 9-hour/night sleep opportunity will be provided throughout the 10-day inpatient visit.
Study NCT05467176 — intervention group
Intervention type: DRUG
Intervention: Relugolix
Description: Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
Study NCT04916002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vidutolimod
Description: Participants will receive vidutolimod for up to 2 years as follows: 10 mg IT weekly for 7 doses after which vidutolimod will be administered every 3 weeks (Q3W). The first dose of vidutolimod may be administered subcutaneously (SC) or IT at the discretion of Investigator. All subsequent doses will be IT. The initial 7 doses of vidutolimod, delivered on a weekly dosing schedule, must be completed before starting the Q3W vidutolimod dosing schedule.
Study NCT04916002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Participants will receive cemiplimab for up to 2 years as follows: 350 mg IV infusion over 30 minutes at week 1 dose 1 (W1D1) and Q3W thereafter.
Study NCT05644444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant A (sensate water-based personal lubricant) and Comparator A (non-sensate water-based lubricant)
Description: In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application.
Study NCT05644444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricant B (sensate silicone-based personal lubricant) and Comparator B (non-sensate silicone-based personal lubricant)
Description: In the tolerance phase, a pea-sized lubricant will be considered a single application for oral assessment and approximately 3g of lubricant will be considered a single application for vaginal assessment.~In the treatment phase, approximately 3g of lubricant will be considered a single application.
Study NCT06122415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma Ab42/Ab40
Description: The cut off will be predefined. The samples will be analysed prospectively every two weeks.
Study NCT06516887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bemcentinib
Description: Bemcentinib has been investigated in a phase I/II clinical trials for solid tumors. Phase I and II clinical studies of BGB324 are ongoing in non-small cell carcinoma, in which combinations with other agents such as Phase I study of docetaxel (NCT02922777), erlotinib (NCT02424617), and pembrolizumab (NCT03184571) are also being investigated. In a phase I dose escalation study of bemcentinib in combination with docetaxel study, patients with treatment naïve, advanced lung adenocarcinoma receive docetaxel 75 mg/m2 given IV every 21 days in combination with bemcentinib. Bemcentinib dose will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
Study NCT06516887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pacritinib
Description: For use in clinical studies as an oral agent, pacritinib is supplied as size #0 hard gelatin capsules with gray bodies and scarlet caps. Capsules contain 100 mg pacritinib (free base) and the following inactive ingredients: microcrystalline cellulose NF, polyethylene glycol 8000 NF, and magnesium stearate NF. The capsule gelatin is bovine derived. Pharmacies at investigational sites will receive subject-specific bottles containing 120 capsules packaged in 200 mL high-density polyethylene bottles with child-resistant closures.
Study NCT06644430 — intervention group
Intervention type: PROCEDURE
Intervention: Ablation
Description: Ablation including (microwave ablation, radiofrequency ablation, cryoblation), this surgery was conducted under CT guidence. The pulmonary was completely ablated.
Study NCT06644430 — intervention group
Intervention type: DRUG
Intervention: system therapy
Description: Paticipants received systemic therapy according the instructions.
Study NCT06015646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized lifestyle coaching and educational handout
Description: Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study. Participants will also receive a 30-minute focused, personalized lifestyle coaching within a week of the initial overnight shift. The lifestyle coach will be in close contact during the night shifts.
Study NCT06015646 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Handout
Description: Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study
Study NCT06015646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handout
Description: Participants will receive a one-page educational handout on strategies to minimize fatigue at the beginning of the study
Study NCT04805346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoRIC®
Description: With the patient sitting upright in bed or a chair, the remote ischemic conditioning intervention will consist of 4 automatic cycles of upper arm blood pressure cuff inflation to 200 mm Hg for 5 minutes to induce transient, noninjurious, limb ischemia, followed by cuff deflation for 5 minutes, for a total of 35 minutes (autoRIC®, Cellaegis Devices, Mississauga, ON, Canada).17 The remote ischemic preconditioning cycles will be performed by trained research personnel prior to each cycle of chemotherapy (total treatments variable based on chemotherapy protocol
Study NCT05489224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P47
Description: CT-P47, 8 mg/kg (not exceeding 800 mg/dose) by intravenous (IV) infusion every 4 weeks (Q4W)
Study NCT05489224 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P47
Description: CT-P47, 8 mg/kg (not exceeding 800 mg/dose) by intravenous (IV) infusion every 4 weeks (Q4W)
Study NCT05489224 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved RoActemra
Description: EU-approved RoActemra, 8 mg/kg (not exceeding 800 mg/dose) by IV infusion Q4W
Study NCT06631885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regenerative endodontic procedure using blood clot according to AAE
Description: regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using AAE protocol
Study NCT06631885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regenerative endodontic procedure using photo activated nanochitosan 2%
Description: regenerative endodontic procedure using blood clot to replace the necrotic pulp tissues in immature teeth with a pulp like to tissue to complete root development. using photosensitized nanochitosan for root canal disinfection
Study NCT05390645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MFA-370
Description: MFA-370 is a treatment with a combination of two approved pharmaceuticals
Study NCT05627648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KP-100LI
Description: Intracordal injection, 20 mcg once per week, 3 weeks
Study NCT05676996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: attachment-based support
Description: attachment-based support application; It includes video-based trainings on attachment via mobile application and breastfeeding and skin-to-skin contact support for mothers on postpartum day 0.
Study NCT05627648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intracordal injection, once per week, 3 weeks
Study NCT04965909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online physiotherapy protocol based on pain neuroscience education and gradual exposure to movement.
Description: Online group therapeutic program (small groups), applied for 3 months.
Study NCT05194709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CAR-NK Cells
Description: The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle (21 days). The first administration dose in the first cycle is 3.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10\^9 cells.
Study NCT05380726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: The intervention received will be a specific patient education for each subject depending on the parameters assessed by the electronic wrist device in real-time. The recommendation are related to different educational topics as hygienic-dietary measures and sleep related habits, or physical activity.
Study NCT05380726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: The intervention received will be a specific patient education for each subject depending on the parameters assessed by the electronic wrist device in real-time. The recommendation are related to different educational topics as hygienic-dietary measures and sleep related habits, or physical activity.
Study NCT06674746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOLUTION FOCUSED APPROACH
Description: The interviews with the control group were planned as eight sessions. There will be defined time intervals between sessions. It is estimated to take 6 months.
Study NCT05683301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine + Perindopril
Description: Single pill combination of dual antihypertensive agent
Study NCT05683301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril + Indapamide
Description: Single pill combination of dual antihypertensive agent
Study NCT05683301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine + Indapamide
Description: Single pill combination of dual antihypertensive agent
Study NCT05373719 — intervention group
Intervention type: OTHER
Intervention: No intervention; observational
Description: No intervention; observational
Study NCT06388187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive once-weekly cagrilintide subcutaneously.
Study NCT06388187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cagrilintide
Description: Participants will receive once-weekly cagrilintide subcutaneously.
Study NCT06388187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once-weekly semaglutide subcutaneously.
Study NCT06388187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive once-weekly semaglutide subcutaneously.
Study NCT06388187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.
Study NCT05879120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV (vein)
Study NCT05879120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate MRgFUS + neoadjuvant pembolizumab
Description: Given by IV (vein)